Mesoblast Limited vs New Era Energy & Digital Inc. Common Stock — how do they compare? Mesoblast Limited trades at $14.32 (market cap $1.75B), while New Era Energy & Digital Inc. Common Stock trades at $4.69 (market cap $583.45M). The key difference: Mesoblast Limited is far larger — about 3× New Era Energy & Digital Inc. Common Stock's market cap, and New Era Energy & Digital Inc. Common Stock is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and New Era Energy & Digital Inc. Common Stock for 0 Days on average.
| MESO | NUAI | |
|---|---|---|
Market Cap | $1.75B | $583.45M |
Volume | 239,027 | 17,217,412 |
Sector | Health | Technology |
52-Week High | $20.96 | $8.06 |
52-Week Low | $13.19 | $2.35 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $1.83B | $528.80M |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →